Results 11 to 20 of about 1,995 (245)

Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine

Expert Review of Vaccines
Background The tetravalent dengue vaccine TAK-003 is contraindicated during pregnancy. Pregnant women were excluded from TAK-003 clinical studies; however, some pregnancies occurred unintentionally.Research design and methods This post-hoc analysis of ...
Martina Rauscher, Zeb Youard, Alice Faccin, Sanjay S. Patel, Hang Pang, Olaf Zent   +5 more
exaly   +12 more sources

The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine [PDF]

npj Vaccines
The approved, live-attenuated tetravalent dengue vaccine TAK-003 has undergone extensive preclinical and clinical assessment. This review provides an overview of the rationale for some key decisions made during TAK-003 development.
Ian Escudero, Dieter Gniel, Shibadas Biswal, Eckhardt Petri, Gonzalo Perez, Mayuri Sharma, John Weil, Derek Wallace   +7 more
doaj   +4 more sources

Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience. [PDF]

PLoS Neglected Tropical Diseases
BackgroundOutbreaks of dengue can overburden hospital systems, drastically reducing capacity for other care. The 2017 dengue serotype 2 (DENV-2) outbreak in Sri Lanka coincided with vaccination in an ongoing phase 3 efficacy trial of a tetravalent dengue
LakKumar Fernando, Randee Kastner, Pujitha Wickramasinghe, Asvini D Fernando, Dulanie Gunasekera, Van Hung Nguyen, Mengya Liu, Inge LeFevre, Derek Wallace, Nicolas Folschweiller, Shibadas Biswal   +10 more
doaj   +4 more sources

TAK-003: development of a tetravalent dengue vaccine

Expert Review of Vaccines
Introduction Dengue incidence has increased over the past few decades. One tetravalent dengue vaccine based on a yellow fever backbone has been approved, but due to increased risk of severe disease in dengue-naïve recipients, its use is limited to ...
XAVIER SAEZ LLORENS, Rodrigo DeAntonio, Pope Kosalaraksa   +2 more
exaly   +5 more sources

The Tolerability of the Dengue Vaccine TAK-003 (Qdenga^®) in German Travelers: The Results of a Prospective Survey [PDF]

Tropical Medicine and Infectious Disease
Background: The global incidence of dengue has markedly increased over the last decades. Consequently, the risk of infection has increased significantly, resulting in record numbers of imported cases in various European countries and elsewhere in 2024 ...
Tomas Jelinek, Juliane Kramm, Maik Wagner, Claudia Jelinek   +3 more
doaj   +5 more sources

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003 [PDF]

Frontiers in Immunology, 2019
The development of an efficacious DENV vaccine has been a long-standing public health priority. However, this effort has been complicated significantly due to the hazard presented by incomplete humoral immunity in mediating immune enhancement of ...
Adam T. Waickman, Heather Friberg, Morgan Gargulak, Amanda Kong, Mark Polhemus, Timothy Endy, Stephen J. Thomas, Richard G. Jarman, Jeffrey R. Currier   +8 more
doaj   +5 more sources

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003) [PDF]

Clinical Infectious Diseases, 2022
Abstract Background Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in both seronegative and seropositive participants and that its ...
Shibadas Biswal, Xavier Sáez-Llorens, Pope Kosalaraksa   +2 more
exaly   +5 more sources

Severe dengue hemorrhagic fever after TAK-003 dengue vaccination: A case report of a potential vaccine-associated adverse reaction

International Journal of Infectious Diseases
We report a severe dengue case that developed symptoms 5 days post-TAK-003 dengue vaccine administration. Whole-genome sequencing confirmed co-detection of all four dengue serotypes with high similarity to vaccine strains, especially DENV-2. This finding
Pinyo Rattanaumpawan
exaly   +5 more sources

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate [PDF]

Clinical Infectious Diseases, 2023
Abstract Background An unmet medical need remains for an effective dengue tetravalent vaccine that can be administered irrespective of previous dengue exposure. TAK-003, a dengue tetravalent vaccine, has demonstrated efficacy in an ongoing phase 3 trial in children and adolescents living in dengue ...
Martina Rauscher
exaly   +4 more sources

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination [PDF]

Journal of Infectious Diseases, 2022
Abstract Background Takeda’s dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update. Methods Children (20 099, 4–16 years old) were randomized to receive 2 doses of TAK-003 or placebo 3 ...
Shibadas Biswal, Xavier Sáez-Llorens, Veerachai Watanaveeradej   +2 more
exaly   +5 more sources